Floatz logo

Pegylated Recombinant Human Hyaluronidase Ph20

Metastatic Breast Cancer

Eisai Inc.Phase 1/2Dormant
D
26/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
11/ 100
Competitive Position
73/ 100

Competitive context

891 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Pegylated Recombinant Human Hyaluronidase Ph20 is also rated in:

pancreatic ductal adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →
pancreatic adenocarcinomaDormant
D
Indicative ·
29 / 100
View asset →
pancreatic adenocarcinomaDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →